(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Dec ...
Stocktwits on MSN
Eli Lilly stock rises after late-stage data shows longer survival with breast cancer drug
The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the ...
Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...
Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) ...
News-Medical.Net on MSN
Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed ...
The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...
Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...
Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...
MedPage Today on MSN
For Your Patients: What to Know About the Newest Treatments for HR+/HER2- Breast Cancer
Resistance to initial therapy sets the stage for many other options ...
An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring ...
Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...
New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback